Johnson & Johnson added Anne Mulcahy, chairman of the board of Xerox, to its board. Mulcalhy spent eight years as CEO of Xerox, retiring last July.
Peregrine Pharmaceuticals hired Dr. Robert Garnick as head of regulatory affairs. Dr. Garnick was formerly senior vice president for regulatory, quality and compliance at Genentech. During his 24-year career at Genentech, he was responsible for 17 new product approvals, including most of the company’s top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin and Lucentis.
